원문정보
초록
영어
The hexosamine biosynthesis pathway (HBP) is an important branch of glycolysis to induced protein O-GlcNAcylation and acts as a glucose sensing in many types of cells. Glucosamine (alternatively named 2-amino-2-deoxy-d-glucose), an intermediate metabolite of the HBP, bypasses glycolysis for directly entering HBP. Since glucosamine stimulates glycosaminoglycan production, it has been extensively studied in the context of osteoarthritis and joint pain. Although several clinical studies conducted on oral supplementation of glucosamine demonstrate its beneficial effects in the progression of osteoarthritis and cartilage renewal, the efficacy of glucosamine for osteoarthritis remains controversial. Furthermore, exogenous glucosamine application exhibits therapeutic effects by increasing protein O-GlcNAcylation. Glucosamine regulates glucose metabolism, insulin resistance, diabetic complications and lipid metabolism. Additionally, glucosamine exerts several beneficial effects on oxidative stress, inflammation, cell proliferation, apoptosis, and growth factor signaling. More recent studies demonstrate that exogenous glucosamine can improve the neurodegeneration and cognitive function induced by sleep deprivation, circadian cycle disruption and hypoxia, emerging glucosamine as a therapeutic benefit for neuronal dysfunction. However, whether increased O-GlcNAcylation by exogenous glucosamine is protective to disease or promotes progression of the disease or is still a matter of debate. Due to the abundance and ubiquitous nature of the HBP and protein O-GlcNAcylation in mammalian cells and potential effects to other signaling pathways, exogenous glucosamine may induce various effects depends on doses, metabolic status, cell and tissue types and species.